CTLA4 and hepatocellular carcinoma: Overall, the robustness of the combined CTLA-4 and PD-1/PD-L1 blockade in front-line treatment of advanced HCC was nicely demonstrated in both HIMALAYA, with durable 5 year OS data, and as well as in CheckMate-9DW with a deep depth of response.